Rhabdomyolysis in an elderly multitreated patient: Multiple drug interactions after statin withdrawal

Journal of the Neurological Sciences

Volumn 336, Issue 1-2, 2014, Pages 284-287

  Ginanneschi, Federica ^a   Volpi, Nila ^a   Giannini, Fabio ^a   Rocchi, Raffaele ^a   Donati, Donatella ^a   Aglianò, Margherita ^a   Lorenzoni, Paola ^a   Rossi, Alessandro ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antidepressants; Antipsychotics; Multitherapy; Ranolazine; Rhabdomyolysis; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CREATININE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYOGLOBIN; POTASSIUM; RANOLAZINE; ROSUVASTATIN; SODIUM CHLORIDE; TRIACYLGLYCEROL;

AGED; ANGINA PECTORIS; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ELECTROMYOGRAM; FALLING; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS ADMINISTRATION; MALAISE; MALE; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PATIENT HISTORY OF THERAPY; PERIODIC MEDICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASTUS LATERALIS MUSCLE; VOMITING;

ANTIDEPRESSANTS; ANTIPSYCHOTICS; MULTITHERAPY; RANOLAZINE; RHABDOMYOLYSIS; STATINS;

AGED; CARDIOVASCULAR AGENTS; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PSYCHOTROPIC DRUGS; RHABDOMYOLYSIS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84892570645     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.10.040     Document Type: Article

References (38)

1. P.J. Poels, and F.J. Gabreëls Rhabdomyolysis: a review of the literature Clin Neurol Neurosurg 95 3 1993 175 192
2. S. Guis, J.P. Mattei, P.J. Cozzone, and D. Bendahan Pathophysiology and clinical presentations of rhabdomyolysis Joint Bone Spine 72 5 2005 382 391
3. M. Dalakas Toxic and drug induced myopathies J Neurol Neurosurg Psychiatry 80 2009 832 838
4. M. Hohenegger Drug induced rhabdomyolysis Curr Opin Pharmacol 12 3 2012 335 339
5. A. Conforti, C. Chiamulera, U. Moretti, S. Colcera, G. Fumagalli, and R. Leone Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases Curr Drug Saf 2 2007 47 63
6. E. Spina, and J. de Leon Metabolic drug interactions with newer antipsychotics: a comparative review Basic Clin Pharmacol Toxicol 100 2007 4 22
7. C. Rowan, A.D. Brinker, P. Nourjah, J. Chang, A. Mosholder, and J.S. Barrett et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors Pharmacoepidemiol Drug Saf 18 2009 301 309
8. International Transporter Consortium, K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, and K.L. Brouwer et al. Membrane transporters in drug development Nat Rev Drug Discov 9 3 2010 215 236
9. Y. Akamine, N. Yasui-Furukori, I. Ieiri, and T. Uno Psychotropic drug-drug interactions involving P-glycoprotein CNS Drugs 26 11 2012 959 973
10. J.D. Wessler, L.T. Grip, J. Mendell, and R.P. Giugliano The P-glycoprotein transport system and cardiovascular drugs J Am Coll Cardiol 25 61(25) 2013 2495 2502
11. P.G. La Guardia, L.C. Alberici, F.G. Ravagnani, R.R. Catharino, and A.E. Vercesi Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation Front Physiol 4 2013 103
12. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
13. M. Needham, V. Fabian, W. Knezevic, P. Panegyres, P. Zilko, and F.L. Mastaglia Progressive myopathy with up-regulation of MHC-I associated with statin therapy Neuromuscul Disord 17 2007 194 200
14. P. Grable-Esposito, H.D. Katzberg, S.A. Greenberg, J. Srinivasan, J. Katz, and A.A. Amato Immune-mediated necrotizing myopathy associated with statins Muscle Nerve 41 2010 185 190
15. M. Del Grande, and L. Christopher-Stine Expanding our understanding of statin myopathy: when is it autoimmune? Int J Clin Rheumatol 7 2012 243 246
16. B. Noel Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review J Eur Acad Dermatol Venereol 21 2007 17 24
17. J. Doan, H. Zakrzewski-Jakubiak, J. Roy, J. Turgeon, and C. Tannenbaum Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy Ann Pharmacother 47 3 2013 324 332
18. B.K. Plesnicar, J.K. Lasic, and A. Plesnicar Quetiapine and elevated creatine phosphokinase (CK) Pharmacopsychiatry 40 2007 203 204
19. J. Velasco-Montes, I. Oriñuela-González, and A.Z. Sanjuán-López Rhabdomyolysis secondary to quetiapine Actas Esp Psiquiatr 40 2012 97 99
20. R.P. Smith, B.N. Puckett, J. Crawford, and R.L. Elliott Quetiapine overdose and severe rhabdomyolysis J Clin Psychopharmacol 24 2004 343 345
21. C.B. Nemeroff, C.L. DeVane, and B.G. Pollock Newer antidepressants and the cytochrome P450 system Am J Psych 153 1996 311 320
22. P. Gareri, C. Segura-García, P. De Fazio, S. De Fazio, and G. De Sarro Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities Ann Pharmacother 43 2009 1354 1359
23. J. Weiss, S.M. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, and W.E. Haefeli Inhibition of P-glycoprotein by newer antidepressants J Pharmacol Exp Ther 305 2003 197 204
24. D.W. Clark, and J. Strandell Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 62 2006 473 479
25. U. Tröger, I. Reiche, M.S. Jepsen, C. Huth, and S.M. Bode-Böger Esomeprazole-induced rhabdomyolysis in a patient with heart failure Intensive Care Med 36 2010 1278 1279
26. V.S. Bebarta, J.A. King, and M. McDonough Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium Am J Emerg Med 26 519 2008 e1 e2
27. W. Li, S. Zeng, L.S. Yu, and Q. Zhou Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management Ther Clin Risk Manag 9 2013 259 271
28. L. Vanhees, J.G. Defoor, D. Schepers, P. Lijnen, B.Y. Peeters, and P.H. Lacante et al. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men J Hypertens 18 1 2000 35 43
29. A. Brucato, M. Bonati, F. Gaspari, G. Colussi, M. Giachetti, and F. Zoppi et al. Tetany and rhabdomyolysis due to surreptitious furosemide - importance of magnesium supplementation J Toxicol Clin Toxicol 31 1993 341 344
30. Y. Nawata, M. Kagami, H. Nakajima, R. Matsumura, T. Sugiyama, and M. Sueishi et al. Chronic salicylate intoxication and rhabdomyolysis in a patient with scleroderma and Sjögren's syndrome J Rheumatol 21 1994 357 359
31. M.C. Michel, C. Foster, H.R. Brunner, and L. Liu A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists Pharmacol Rev 13 65(2) 2013 809 848
32. M. Govoni, P. Tocchetti, and J.O. Lundberg Metabolism and pathways for denitration of organic nitrates in the human liver J Pharmacol Exp Ther 346 1 2013 96 104
33. H.J. Ryu, R. Song, H.W. Kim, J.H. Kim, E.Y. Lee, and Y.J. Lee et al. Clinical risk factors for adverse events in allopurinol users J Clin Pharmacol 53 2 2013 211 216
34. H. Terawaki, T. Suzuki, K. Yoshimura, T. Hasegawa, H. Takase, and T. Nemoto et al. A case of allopurinol-induced muscular damage in a chronic renal failure patient Nihon Jinzo Gakkai Shi 44 2002 50 53
35. M. Jerling Clinical pharmacokinetics of ranolazine Clin Pharmacokinet 45 2006 469 491
36. S.I. Rifkin Multiple drug interactions in a renal transplant patient lead to simvastatin induced rhabdomyolysis: a case report Medscape J Med 10 2008 264
37. A.C. Hylton, and T.O. Ezekiel Rhabdomyolysis in a patient receiving ranolazine and simvastatin Am J Health-Syst Pharm 67 2010 1829 1831
38. E. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm Res 18 6 2001 800 806